Stipple Bio Launches with $100M Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline April 7, 2026
OnKure Therapeutics Announces Oversubscribed $150M Private Placement to Advance Two PI3Kα Pan-Mutant Selective Inhibitors in Breast Cancer and Vascular Anomalies April 7, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer April 7, 2026
Voro Therapeutics and Daiichi Sankyo to Advance PrimeBody™ Technology for Next-Gen Tumor-Activated ADCs March 24, 2026
Novartis entered into an agreement with Synnovation Therapeutics to acquire SNV4818 for HR+/HER2- breast cancer and other solid tumor indications March 24, 2026
Crossbow Therapeutics raised $77 million in Series B financing to support completion of CROSSCHECK‑001 Ph 1 clinical trial of CBX‑250, and accelerate development of additional T‑Bolt™ immunotherapies March 24, 2026
GlycoNex Inc. and Nippon Kayaku Enter Collaboration to Advance Next-Gen ADC Candidate GNX201-ADC March 24, 2026
Excalipoint Therapeutics Launches with $68.7 Million to Develop Next-Gen T-Cell Engager Therapies March 24, 2026
Erasca and Tango Therapeutics to Evaluate Combination of ERAS-0015 and Vopimetostat in MTAPdel pancreatic or MTAPdel RASm NSCLC March 10, 2026
Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Ph 1b/2a Agent and Announces First Close of Seed Financing March 10, 2026
Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program March 10, 2026
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. March 10, 2026
Tempus Announces Strategic Collaboration Agreement with Merck to Accelerate AI-Driven Precision Medicine March 10, 2026
AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8M March 10, 2026
Hopewell Therapeutics Announces Sublicense of Proprietary Lipid Nanoparticles for Novel Cancer Vaccine to Foxcroft Therapeutics March 10, 2026
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission March 10, 2026
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio March 10, 2026
Astellas and Vir Biotechnology to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer March 3, 2026
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform March 3, 2026
